Lowered levels of carbonyl proteins after Vitamin B supplementation in patients with mild cognitive impairment and Alzheimer's disease

Neurodegenerative Diseases

Volumn 16, Issue 3-4, 2016, Pages 284-289

  Rommer, Paulus S ^a   Fuchs, Dietmar ^b   Leblhuber, Friedrich ^c   Schroth, Rainer ^d   Greilberger, Michaela ^e   Tafeit, Erwin ^f   Greilberger, Joachim ^f  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^c Landes Nervenklinik ^*  (Austria)

^d Sonderkrankenanstalt Die Schrothkur   (Austria)

^e Schwarzl Medical Center   (Austria)

^f MEDICAL UNIVERSITY OF GRAZ   (Austria)

Author keywords

Alzheimer's disease; Biomarker; Carbonyl proteins; Neurodegenerative disease; Oxidative stress; Vitamin B supplementation

Indexed keywords

BIOLOGICAL MARKER; CARBONYL DERIVATIVE; CARBONYL PROTEIN; CYANOCOBALAMIN; FOLIC ACID; KYNURENINE; MALONALDEHYDE; NEOPTERIN; PYRIDOXINE; THIAMINE; TRYPTOPHAN; UNCLASSIFIED DRUG; VITAMIN B COMPLEX;

ADULT; AGED; ALZHEIMER DISEASE; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; COGNITION; CONTROLLED STUDY; CORRELATION COEFFICIENT; ENCEPHALITIS; FEMALE; FOLIC ACID BLOOD LEVEL; GROUPS BY AGE; HUMAN; MALE; MIDDLE AGED; MILD COGNITIVE IMPAIRMENT; MINI MENTAL STATE EXAMINATION; OPEN STUDY; OXIDATIVE STRESS; PRIORITY JOURNAL; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY; TREATMENT DURATION; VITAMIN BLOOD LEVEL; VITAMIN SUPPLEMENTATION; AGE; CLINICAL TRIAL; COGNITIVE DYSFUNCTION; DIET THERAPY; DIETARY SUPPLEMENT; DISCRIMINANT ANALYSIS; MENTAL HEALTH; METABOLISM; PSYCHOLOGY; TREATMENT OUTCOME;

AGE FACTORS; AGED; ALZHEIMER DISEASE; BIOMARKERS; COGNITIVE DYSFUNCTION; DIETARY SUPPLEMENTS; DISCRIMINANT ANALYSIS; FEMALE; FOLIC ACID; HUMANS; KYNURENINE; MALE; MENTAL STATUS SCHEDULE; MIDDLE AGED; ROC CURVE; THIAMINE; TREATMENT OUTCOME; TRYPTOPHAN; VITAMIN B 12; VITAMIN B 6; VITAMIN B COMPLEX;

EID: 84947780634     PISSN: 16602854     EISSN: 16602862     Source Type: Journal    
DOI: 10.1159/000441565     Document Type: Article

References (30)

1. Alzheimer s Disease International (ADI): The global impact of dementia 2013-2050. London, Alzheimer s Disease International, 2013. http://www.alz.co.uk/research/GlobalImpactDementia2013. pdf (accessed January 16, 2015)
2. Schaller S, Mauskopf J, Kriza C, Wahlster P, Kolominsky-Rabas PLàmain cost drivers in dementia: a systematic review. Int J Geriatr Psychiatry 2015; 30: 111-129
3. Jack CR Jr, Albert MS, Knopman DS,. et al. Introduction to the recommendations from the National Institute on Aging-Alzheimer s Association workgroups on diagnostic guidelines for Alzheimer s disease. Alzheimers Dement 2011; 7: 257-262
4. Eschweiler GW, Leyhe T, Kloppel S, Hull M. New developments in the diagnosis of dementia. Dtsch Arztebl Int 2010; 107: 677-683
5. Takeda S, Sato N, Morishita R. Systemic inflammation, blood-brain barrier vulnerability and cognitive/non-cognitive symptoms in Alzheimer disease: relevance to pathogenesis and therapy. Front Aging Neurosci 2014; 6: 171
6. Dal Bianco A, Bradl M, Frischer J, Kutzelnigg A, Jellinger K, Lassmann H. Multiple sclerosis and Alzheimer s disease. Ann Neurol 2008; 63: 174-183
7. Singhal G, Jaehne EJ, Corrigan F, Toben C, Baune BT. Inflammasomes in neuroinflammation and changes in brain function: a focused review. Front Neurosci 2014; 8: 315
8. Parker DC, Mielke MM, Yu Q,. et al. Plasma neopterin level as a marker of peripheral immune activation in amnestic mild cognitive impairment and Alzheimer s disease. Int J Geriatr Psychiatry 2013; 28: 149-154
9. Porter RJ, Lunn BS, O Brien JT. Effects of acute tryptophan depletion on cognitive function in Alzheimer s disease and in the healthy elderly. Psychol Med 2003; 33: 41-49
10. Nielsen F, Mikkelsen BB, Nielsen JB, Andersen HR, Grandjean P. Plasma malondialdehyde as biomarker for oxidative stress: reference interval and effects of life-style factors. Clin Chem 1997; 43: 1209-1214
11. Majlath Z, Tajti J, Vecsei L. Kynurenines and other novel therapeutic strategies in the treatment of dementia. Ther Adv Neurol Disord 2013; 6: 386-397
12. Schrag M, Mueller C, Zabel M,. et al. Oxidative stress in blood in Alzheimer s disease and mild cognitive impairment: a meta-analysis. Neurobiol Dis 2013; 59: 100-110
13. Rommer PS, Greilberger J, Salhofer-Polanyi S, Auff E, Leutmezer F, Herwig R. Elevated levels of carbonyl proteins in cerebrospinal fluid of patients with neurodegenerative diseases. Tohoku J Exp Med 2014; 234: 313-317
14. Greilberger J, Fuchs D, Leblhuber F, Greilberger M, Wintersteiger R, Tafeit E. Carbonyl proteins as a clinical marker in Alzheimer s disease and its relation to tryptophan degradation and immune activation. Clin Lab 2010; 56: 441-448
15. Frick B, Gruber B, Schroecksnadel K, Leblhuber F, Fuchs D. Homocysteine but not neopterin declines in demented patients on B vitamins. J Neural Transm 2006; 113: 1815-1819
16. Seshadri S, Beiser A, Selhub J,. et al. Plasma homocysteine as a risk factor for dementia and Alzheimer s disease. N Engl J Med 2002; 346: 476-483
17. Guttormsen AB, Ueland PM, Nesthus I,. et al. Determinants and vitamin responsiveness of intermediate hyperhomocysteinemia (> or =micromol/liter)àHordaland Homocysteine Study. J Clin Invest 1996; 98: 2174-2183
18. Chen H, Liu S, Ji L, Wu T, Ma F,. et al. Associations between Alzheimer s disease and blood homocysteine, vitamin B 12 , and folate: a case-control study. Curr Alzheimer Res 2015; 12: 88-94
19. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer s disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer s Disease. Neurology 1984; 34: 939-944
20. Petersen RC, Smith GE, Waring SC, Ivnik RJ, Tangalos EG, Kokmen E. Mild cognitive impairment: clinical characterization and outcome. Arch Neurol 1999; 56: 303-308
21. Frick B, Schrocksnadel K, Neurauter G, Wirleitner B, Artner-Dworzak E, Fuchs D. Rapid measurement of total plasma homocysteine by HPLC. Clin Chim Acta 2003; 331: 19-23
22. Greilberger J, Koidl C, Greilberger M,. et al. Malondialdehyde, carbonyl proteins and albumin-disulphide as useful oxidative markers in mild cognitive impairment and Alzhei mer s disease. Free Radic Res 2008; 42: 633-638
23. Horejsi R, Moller R, Pieber TR,. et al. Differences of subcutaneous adipose tissue topography between type-2 diabetic men and healthy controls. Exp Biol Med (Maywood) 2002; 227: 794-798
24. Tafeit E, Moller R, Sudi K, Reibnegger G. ROC and CART analysis of subcutaneous adipose tissue topography (SAT-Top) in type-2 diabetic women and healthy females. Am J Hum Biol 2000; 12: 388-394
25. Theofylaktopoulou D, Ulvik A, Midttun O,. et al. Vitamins B 2 and B 6 as determinants of kynurenines and related markers of interferon-γ-mediated immune activation in the community-based Hordaland Health Study. Br J Nutr 2014; 112: 1065-1072
26. Birch CS, Brasch NE, McCaddon A, Williams JH. A novel role for vitamin B(12): cobalamins are intracellular antioxidants in vitro. Free Radic Biol Med 2009; 47: 184-188
27. Qin L, Wang W, You S, Dong J, Zhou Y, Wang J. In vitro antioxidant activity and in vivo antifatigue effect of layered double hydroxide nanoparticles as delivery vehicles for folic acid. Int J Nanomed 2014; 9: 5701-5710
28. Stanger O, Fowler B, Piertzik K,. et al. Homocysteine, folate and vitamin B 12 in neuropsychiatric diseases: review and treatment recommendations. Expert Rev Neurother 2009; 9: 1393-1412
29. Snyder PJ, Kahle-Wrobleski K, Brannan S,. et al. Assessing cognition and function in Alzheimer s disease clinical trials: do we have the right tools?. Alzheimers Dement 2014; 10: 853-860
30. Dysken MW, Sano M, Asthana S,. et al. Effect of vitamin E and memantine on functional decline in Alzheimer disease: the TEAM-AD VA cooperative randomized trial. JAMA 2014; 311: 33-44